These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8226934)

  • 1. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA.
    Lawrence DL; Engelsberg BN; Farid RS; Hughes EN; Billings PC
    J Biol Chem; 1993 Nov; 268(32):23940-5. PubMed ID: 8226934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential binding of HMG1, HMG2, and a single HMG box to cisplatin-damaged DNA.
    Farid RS; Bianchi ME; Falciola L; Engelsberg BN; Billings PC
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):532-9. PubMed ID: 8975778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
    Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
    Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2.
    Hughes EN; Engelsberg BN; Billings PC
    J Biol Chem; 1992 Jul; 267(19):13520-7. PubMed ID: 1618852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin.
    Cryer JE; Johnson SW; Engelsberg BN; Billings PC
    Cancer Chemother Pharmacol; 1996; 38(2):163-8. PubMed ID: 8616907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein.
    Turchi JJ; Li M; Henkels KM
    Biochemistry; 1996 Mar; 35(9):2992-3000. PubMed ID: 8608137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteins binding to cisplatin-damaged DNA in human cell lines.
    Billings PC; Engelsberg BN; Hughes EN
    Cancer Invest; 1994; 12(6):597-604. PubMed ID: 7994594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual function of Ixr1 in transcriptional regulation and recognition of cisplatin-DNA adducts is caused by differential binding through its two HMG-boxes.
    Vizoso-Vázquez A; Lamas-Maceiras M; Fernández-Leiro R; Rico-Díaz A; Becerra M; Cerdán ME
    Biochim Biophys Acta Gene Regul Mech; 2017 Feb; 1860(2):256-269. PubMed ID: 27871851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
    Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
    Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin.
    Chao JC; Wan XS; Engelsberg BN; Rothblum LI; Billings PC
    Biochim Biophys Acta; 1996 Jun; 1307(2):213-9. PubMed ID: 8679707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin.
    Yarnell AT; Oh S; Reinberg D; Lippard SJ
    J Biol Chem; 2001 Jul; 276(28):25736-41. PubMed ID: 11344167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
    Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-DNA damage recognition proteins in human tumour extracts.
    Bissett D; McLaughlin K; Kelland LR; Brown R
    Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.
    Arioka H; Nishio K; Ishida T; Fukumoto H; Fukuoka K; Nomoto T; Kurokawa H; Yokote H; Abe S; Saijo N
    Jpn J Cancer Res; 1999 Jan; 90(1):108-15. PubMed ID: 10076573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-mobility group 1 protein inhibits helicase catalyzed displacement of cisplatin-damaged DNA.
    Patrick SM; Henkels KM; Turchi JJ
    Biochim Biophys Acta; 1997 Nov; 1354(3):279-90. PubMed ID: 9427537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two mutations of basic residues within the N-terminus of HMG-1 B domain with different effects on DNA supercoiling and binding to bent DNA.
    Stros M
    Biochemistry; 2001 Apr; 40(15):4769-79. PubMed ID: 11294645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase CK2 phosphorylates the high mobility group domain protein SSRP1, inducing the recognition of UV-damaged DNA.
    Krohn NM; Stemmer C; Fojan P; Grimm R; Grasser KD
    J Biol Chem; 2003 Apr; 278(15):12710-5. PubMed ID: 12571244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin.
    Bruhn SL; Pil PM; Essigmann JM; Housman DE; Lippard SJ
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2307-11. PubMed ID: 1372440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism.
    Locker D; Decoville M; Maurizot JC; Bianchi ME; Leng M
    J Mol Biol; 1995 Feb; 246(2):243-7. PubMed ID: 7869375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.